Viridian Metals Inc

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Viridian Metals Clarifies Disclosure

Viridian Announces Market Services Agreement With Outside The Box Capital

Viridian Metals Secures $225,000 Maximum JEA Funding; Adopts Quarterly Reporting Exemption